The WNT/β-catenin signaling inhibitor XAV939 enhances the elimination of LNCaP and PC-3 prostate cancer cells by prostate cancer patient lymphocytes in vitro.
Aged
Antineoplastic Agents
/ pharmacology
CD4-Positive T-Lymphocytes
/ drug effects
Cell Line, Tumor
Heterocyclic Compounds, 3-Ring
/ pharmacology
Humans
Immunotherapy
/ methods
Male
Middle Aged
PC-3 Cells
Prostatic Neoplasms
/ drug therapy
T-Lymphocytes
/ cytology
Tankyrases
/ antagonists & inhibitors
Wnt Proteins
/ antagonists & inhibitors
Wnt Signaling Pathway
/ drug effects
beta Catenin
/ antagonists & inhibitors
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 03 2019
18 03 2019
Historique:
received:
28
11
2018
accepted:
28
02
2019
entrez:
20
3
2019
pubmed:
20
3
2019
medline:
2
10
2020
Statut:
epublish
Résumé
Upregulated Wnt/β-catenin signaling is associated with increased cancer cell resistance and cancer cell-elicited immunosuppression. In non-neoplastic immune cells, upregulated Wnt/β-catenin is, however, associated with either immunosuppression or immunostimulation. Therefore, it is difficult to predict the therapeutic impact inhibitors of Wnt/β-catenin signaling will have when combined with cancer immunotherapy. Here, we evaluated the benefit(s) of the Wnt/β-catenin signaling inhibitor XAV939 in the in vitro elimination of LNCaP prostate cancer cells when cocultured with lymphocytes from patients with localized biochemically recurrent prostate cancer (BRPCa). We found that 5 µM XAV939 inhibited β-catenin translocation to the nucleus in LNCaP cells and CD4
Identifiants
pubmed: 30886380
doi: 10.1038/s41598-019-41182-5
pii: 10.1038/s41598-019-41182-5
pmc: PMC6423115
doi:
Substances chimiques
Antineoplastic Agents
0
CTNNB1 protein, human
0
Heterocyclic Compounds, 3-Ring
0
Wnt Proteins
0
XAV939
0
beta Catenin
0
Tankyrases
EC 2.4.2.30
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4761Références
Oncologist. 2013 Jun;18(6):687-8
pubmed: 23740935
Clin Cancer Res. 2010 Oct 1;16(19):4695-701
pubmed: 20688898
J Thorac Oncol. 2015 Jan;10(1):93-101
pubmed: 25384171
Oncol Lett. 2017 Dec;14(6):6585-6591
pubmed: 29344117
Front Immunol. 2016 Oct 27;7:460
pubmed: 27833613
Cancer Res. 2015 Apr 1;75(7):1482-94
pubmed: 25670168
Invest Urol. 1979 Jul;17(1):16-23
pubmed: 447482
Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):2823-8
pubmed: 25730849
Mol Cancer Res. 2017 Nov;15(11):1481-1490
pubmed: 28811361
Oncogene. 2017 Apr;36(15):2105-2115
pubmed: 27775078
J Immunol. 2012 Sep 1;189(5):2110-7
pubmed: 22815287
Cancer Cell. 2011 Dec 13;20(6):741-54
pubmed: 22172720
PLoS One. 2015 Oct 28;10(10):e0141589
pubmed: 26509262
EMBO J. 2012 Jun 13;31(12):2714-36
pubmed: 22617422
Oncology (Williston Park). 2018 Jun 15;32(6):e65-e73
pubmed: 29940064
Oncology (Williston Park). 2018 Mar 15;32(3):112-20
pubmed: 29548065
Adv Drug Deliv Rev. 2017 Jan 15;109:63-73
pubmed: 26877102
Science. 2010 Aug 13;329(5993):849-53
pubmed: 20705860
J Immunol Methods. 2018 Jul;458:63-73
pubmed: 29684429
Oncotarget. 2016 Nov 29;7(48):78896-78909
pubmed: 27806331
Protein Sci. 2017 Apr;26(4):650-661
pubmed: 28120389
Nat Med. 2012 Sep;18(9):1359-68
pubmed: 22863786
Cancer Res. 2018 Jun 15;78(12):3147-3162
pubmed: 29700003
Cancers (Basel). 2016 Jun 27;8(7):
pubmed: 27355964
J Hematol Oncol. 2017 May 5;10(1):101
pubmed: 28476164
Oncol Lett. 2018 Jun;15(6):8973-8982
pubmed: 29805633
Nature. 2009 Oct 1;461(7264):614-20
pubmed: 19759537
Mol Cancer Ther. 2018 Feb;17(2):544-553
pubmed: 29282298
Eur J Pharmacol. 2009 Jan 5;602(1):8-14
pubmed: 19026633
Eur J Med Chem. 2017 Dec 15;142:506-522
pubmed: 29107427
Cancer Res. 1983 Apr;43(4):1809-18
pubmed: 6831420
PLoS One. 2016 Mar 25;11(3):e0152407
pubmed: 27014877
Cancer Treat Rev. 2018 Jan;62:50-60
pubmed: 29169144
Carcinogenesis. 2017 Feb 1;38(2):107-118
pubmed: 27866156
Eur Urol. 2014 Jul;66(1):32-9
pubmed: 24054872
J Immunol. 2011 Jan 15;186(2):784-90
pubmed: 21149602
Nat Med. 2008 Feb;14(2):162-9
pubmed: 18246080
Mediators Inflamm. 2016;2016:6235614
pubmed: 27069316
Oncol Lett. 2018 Aug;16(2):1953-1958
pubmed: 30008888
Br J Pharmacol. 2017 Dec;174(24):4611-4636
pubmed: 28910490
Cell Signal. 2017 Dec;40:30-43
pubmed: 28844868
Med Oncol. 2017 Sep 2;34(10):173
pubmed: 28866803
J Natl Cancer Inst. 2014 Sep 24;106(11):
pubmed: 25255802
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
Cancer Immunol Immunother. 2018 Jan;67(1):89-100
pubmed: 28948333
Eur J Immunol. 2010 Dec;40(12):3557-69
pubmed: 21108475
Cell. 2017 Jun 1;169(6):985-999
pubmed: 28575679
Sci Rep. 2015 Jul 23;5:12465
pubmed: 26202299